Scaling Innovation: Swiss Biotech’s Hiring Surge in 2025
A Thriving Biotech Ecosystem in Switzerland
Switzerland’s biotech landscape in 2025 is set to be vibrant and rapidly evolving, fuelled by strong domestic innovation and global trends in pharmaceuticals and life sciences. The country’s biotech sector has been steadily expanding, with many small to mid-sized companies making significant strides in areas such as oncology, gene therapy, and precision medicine. These firms are well-positioned to drive forward new breakthroughs, reinforcing Switzerland’s status as a key hub for biotech innovation.
Turbocharging Clinical Operations Teams
As Swiss biotech companies secure funding, expanding their clinical operations teams will be a major focus in 2025, especially as many firms transition from preclinical to clinical trials. Clinical trial activity is anticipated to surge in key areas like oncology, rare diseases, neurology, gene therapies, and mRNA technologies—fields currently witnessing significant investment and innovation. According to Evaluate Pharma, the global biotech market is expected to grow at a compound annual growth rate (CAGR) of 9.4%, reaching $775 billion by 2026. As a leader in this space, Switzerland is poised to make a substantial contribution to this growth.
Oncology: The Frontline of Innovation
Oncology continues to be the largest area of focus for Swiss biotech’s. Companies such as AC Immune and Idorsia are at the forefront of advancements in targeted therapies and immuno-oncology. The global oncology market is forecasted to grow by 12% annually, driven by innovations like CAR-T therapies, checkpoint inhibitors, and next-generation sequencing. As these therapies advance, the demand for clinical operations teams to manage complex, multi-site trials will rise significantly.
The mRNA Revolution: Transforming Treatment
mRNA technology is another field poised for significant growth, particularly following the success of COVID-19 vaccines. Firms such as Arcturus Therapeutics and Anjarium Biosciences are exploring mRNA platforms to address conditions like cancer and rare genetic disorders. The mRNA therapeutics market is projected to grow by 13.6% annually, reaching £23.4 billion by 2030, with much of this development occurring in Switzerland. As mRNA therapies progress into advanced clinical stages, the need for clinical operations teams to navigate regulatory and manufacturing challenges will increase.
Pioneering Solutions for Rare Diseases
Rare diseases and gene therapies are additional areas where Switzerland excels. Companies like CRISPR Therapeutics and UniQure are leading advancements in gene-editing technologies. The European Medicines Agency has reported a 25% year-on-year increase in gene therapy trial applications, a momentum expected to continue. To manage these complex trials effectively, biotech firms will need to scale up their clinical operations teams to address regulatory compliance and patient recruitment challenges.
For the full report click here
Arnold Bokumbe - Head of Research & Development | Cpl UK + Europe